| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia ML Davila, I Riviere, X Wang, S Bartido, J Park, K Curran, SS Chung, ... Science translational medicine 6 (224), 224ra25-224ra25, 2014 | 2983 | 2014 |
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma … J BladÉ, D Samson, D Reece, J Apperley, B BJÖrkstrand, G Gahrton, ... British journal of haematology 102 (5), 1115-1123, 1998 | 2018 | 1998 |
| Defining the intensity of conditioning regimens: working definitions A Bacigalupo, K Ballen, D Rizzo, S Giralt, H Lazarus, V Ho, J Apperley, ... Biology of blood and marrow transplantation 15 (12), 1628-1633, 2009 | 1916 | 2009 |
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. RH Collins Jr, O Shpilberg, WR Drobyski, DL Porter, S Giralt, R Champlin, ... Journal of clinical oncology 15 (2), 433-444, 1997 | 1575 | 1997 |
| Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy S Giralt, E Estey, M Albitar, K Van Besien, G Rondón, P Anderlini, ... Blood, The Journal of the American Society of Hematology 89 (12), 4531-4536, 1997 | 1492 | 1997 |
| Lenalidomide after stem-cell transplantation for multiple myeloma PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ... New England Journal of Medicine 366 (19), 1770-1781, 2012 | 1373 | 2012 |
| Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for … IF Khouri, M Keating, M Körbling, D Przepiorka, P Anderlini, S O'Brien, ... Journal of Clinical Oncology 16 (8), 2817-2824, 1998 | 1157 | 1998 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 985 | 2012 |
| The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation Y Taur, RR Jenq, MA Perales, ER Littmann, S Morjaria, L Ling, D No, ... Blood, The Journal of the American Society of Hematology 124 (7), 1174-1182, 2014 | 894 | 2014 |
| Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research S Giralt, K Ballen, D Rizzo, A Bacigalupo, M Horowitz, M Pasquini, ... Biology of Blood and Marrow Transplantation 15 (3), 367-369, 2009 | 875 | 2009 |
| Intestinal Blautia is associated with reduced death from graft-versus-host disease RR Jenq, Y Taur, SM Devlin, DM Ponce, JD Goldberg, KF Ahr, ... Biology of Blood and Marrow Transplantation 21 (8), 1373-1383, 2015 | 772 | 2015 |
| Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell … S Giralt, PF Thall, I Khouri, X Wang, I Braunschweig, C Ippolitti, D Claxton, ... Blood, The Journal of the American Society of Hematology 97 (3), 631-637, 2001 | 707 | 2001 |
| Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome JA Coppell, PG Richardson, R Soiffer, PL Martin, NA Kernan, A Chen, ... Biology of blood and marrow transplantation 16 (2), 157-168, 2010 | 695 | 2010 |
| Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments] M Korbling, D Przepiorka, YO Huh, H Engel, K Van Besien, S Giralt, ... | 686 | 1995 |
| Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse SJ Lee, JP Klein, AJ Barrett, O Ringden, JH Antin, JY Cahn, MH Carabasi, ... Blood, The Journal of the American Society of Hematology 100 (2), 406-414, 2002 | 670 | 2002 |
| Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes BL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, ... Journal of Clinical Oncology 35 (11), 1154-1161, 2017 | 643 | 2017 |
| Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation JU Peled, ALC Gomes, SM Devlin, ER Littmann, Y Taur, AD Sung, ... New England Journal of Medicine 382 (9), 822-834, 2020 | 564 | 2020 |
| Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with … BL McClune, DJ Weisdorf, TL Pedersen, G Tunes da Silva, MS Tallman, ... Journal of Clinical Oncology 28 (11), 1878-1887, 2010 | 560 | 2010 |
| Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ... Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011 | 553 | 2011 |
| Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group MA Dimopoulos, E Terpos, A Chanan-Khan, N Leung, H Ludwig, ... Journal of clinical oncology 28 (33), 4976-4984, 2010 | 550 | 2010 |
